The data of Simon et al. showed that the prevalence of malignancies in RA patients is a two-fold increase in lung cancer compared to the general population, particularly in patients treated with MTX compared to biologic DMARDs, predominantly TNF inhibitors [17]. The gene discussed is TNF; the disease is lung cancer.